The folic acid and neural tube defects – from past to present

1. Czeizel AE. The primary prevention of birth defects: Multivitamins or folic acid? Int J Med Sci 2004; 1: 50–61.

2. Mitchell LE. Epidemiology of neural tube defects. Am J Med Genet C Semin Med Genet 2005; 135: 88–94.

3. Manning N, Archer N. Treatment and outcome of serious structural congenital heart disease. Semin Neonatol 2001; 6: 37–47.

4. Vojtassák J, Malová J, Demjenová L, et al. Developmental defects and chromosomal aberrations in spontaneous abortions and stillbirths. Gen Physiol Biophys 1999; 18: 182–188.

5. Šípek A, Horáček J, Gregor V, et al. Neural tube defects in the Czech Republic during 1961–1999: incidences, prenatal diagnosis and prevalences according to maternal age. J Obstet Gynaecol 2002; 22: 501–507.

6. Behunová J, Podracká L. Rázštepy nervovej trubice – súčasné pohľady na etiopatogenézu a možnosť prevencie kyselinou listovou. Čes-slov Pediat 2008; 63: 38–46.

7. Copp AJ, Greene NDE. Genetics and development of neural tube defects. J Pathol 2010; 220: 217–230.

8. Šabová L, Horn F, Drdulová T, et al. Clinical condition of patients with neural tube defects. Rozhl Chir 2010; 89: 471–477.

9. Horn F, Smrek M, Babala J, et al. Kraniálne defekty neurálnej rúry. Čes Slov Neurol N 2010; 73: 706–710.

10. Shurtleff DB, Luthy DA, Nyberg DA, et al. Meningomyelocele: managment in utero and post natum. Ciba Found Symp 1994; 181: 270–286.

11. Hunt GM. The median survival time in open spina bifida. Dev Med Child Neurol 1997; 39: 568.

12. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet 1991; 338: 131–137.

13. Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832–1835.

14. Center Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992; 41: 1–7.

15. Volcik KA, Blanton SH, Kruzel MC, et al. Testing for genetic associations in a spina bifida population: analysis of the HOX gene family and human candidate gene regions implicated by mouse models of neural tube defects. Am J Med Genet 2002; 110: 203–207.

16. Frey L, Hauser WA. Epidemiology of neural tube defects. Epilepsia 2003; 44: 4–13.

17. Padmanabhan R. Etiology, pathogenesis and prevention of neural tube defects. Cong Anomal 2006; 46: 55–67.

18. Padmanabhan R. Scanning-electron-microscopic studies on the pathogenesis of exencephaly and cranioschisis induced in the rat after neural tube closure. Acta Anat (Basel) 1990; 138: 97–110.

19. Van Allen MI. Multisite neural tube closure in humans. Birth Defects Orig Arctic Ser 1996; 30: 203–225.

20. Seller MJ, Kalousek DK. Neural tube defects: heterogeneity and homogeneity. Am J Med Genet Suppl 1986; 2: 77–87.

21. Velie EM, Shaw GM, Malcoe LH, et al. Understanding the increased risk of neural tube defect-affected pregnancies among Mexico-born women in California: immigration and anthropometric factors. Paediatr Perinat Epidemiol 2006; 20: 219–230.

22. Shepard TH, Brent RL, Friedman JM, et al. Update on new developments in the study of human teratogens. Teratology 2002; 65: 153–161.

23. Ray JG, Vermeulen MJ, Meier C, Wyatt PR. Risk of congenital anomalies detected during antenatal serum screening in women with pregestational diabetes. QJM 2004; 97: 651–653.

24. Vašut K, Anděl T, Kolář J. Hypertermia v těhotenství – rizika a možnosti léčby. Prakt Gyn 2004; 6: 25–27.

25. Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology 2005; 16: 216–219.

26. Suarez L, Felkner M, Hendricks K. The effect of fever, febrile illnesses, and heat exposures on the risk of neural tube defects in a Texas-Mexico border population. Birth Defects Res A Clin Mol Teratol 2004; 70: 815–809.

27. Hoffbrand AV, Weir DG. Historical review. The history of folic acid. Br J Haematol 2001; 113: 579–589.

28. Mitchell HK, Snell EE, Williams RJ. The concentration of „folic acid“. J Am Chem Soc 1941; 63: 2284.

29. Šabová L, Kovács L. Kyselina listová a vrodené vývojové chyby. Pediatr Prax 2008; 1: 36–38.

30. Smithells RW, Sheppard S, Schorah CJ. Vitamin deficiencies and neural tube defects. Arch Dis Child 1976; 51: 944–949.

31. Johnson WG, Stenroos ES, Heath SC, et al. Distribution of alleles of the methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism in familial spina bifida. Am J Med Genet 1999; 87: P407–P412.

32. Finnell R, Spiegelstein O, Wlodarczyk B, et al. DNA methylation in Folbp1 knockout mice supplemented with folic acid during gestation. J Nutr 2002; 132: 2457S–2461S.

33. Boot MJ, Steegers-Theunissen RPM, Poelmann RE, et al. Folic acid and homocysteine affect neural crest and neuroepithelial cell outgrowth and differentiation in vitro. Dev Dyn 2003; 227: 301–308.

34. Mathers JC. Reversal of DNA hypomethylation by folic acid supplements: Possible role in colorectal prevention. Gut 2005; 54: 579–581.

35. Biniszkiewicz D, Girbnau J, Ramsahoye B, et al. Dnmt1 overexpression causes genomic hypermethylation. Loss of imprinting, and embryonic lethality. Mol Cell Biol 2002; 22: 2124–2328.

36. Jackson M, Krassowska A, Gilbert N, et al. Severe global DNA hypomethylation blocks differentiation and induces histone hyperacetylation in embryonic stem cells. Mol Cell Biol 2004; 24: 8862–8871.

37. Santos F, Hendrich B, Dean W. Dynamic reprogramming of DNA methylation in the early mouse embryo. Dev Biol 2002; 241: 172–182.

38. Jackson-Grusby L, Beard C, Possemato R, et al. Loss of genomic methylation causes p53 dependent apoptosis and epigenic deregulation. Nat Genet 2001; 27:31–39.

39. Bohnsack BL, Hirschi KK. Nutrient regulation of cell cycle progression. Annu Rev Nutr 2004; 24: 433–453.

40. Greene NDE, Stanier P, Copp AJ. Genetics of human neural tube defects. Hum Mol Genet 2009; 18: R113–R129.

41. Van der Linden IJ, Afman LA, Heil SG, et al. Genetic variation in genes of folate metabolism and neural-tube defect risk. Proc Nutr Soc 2006; 65: 204–215.

42. Boyles AL, Billups AV, Deak KL, et al. Neural tube defects and folate pathway genes: Family-based association tests of gene-gene and gene-environment interactions. Environ Health Perspect 2006; 114: 1547–1552.

43. De Marco P, Calevo M, Moroni A, et al. Reduced folate carrier polymorphism (80A—>G) and neural tube defects. Eur J Hum Genet 2003; 11: 245–252.

44. O’Leary VB, Pangilinan F, Cox C, et al. Reduced folate carrier polymorphisms and neural tube defect risk. Mol Genet Metab 2006; 87: 364–369.

45. Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070–1071.

46. Shields DC, Kirke PN, Mills JL, et al. The ‘thermolabile’ variant of methylenetetrahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet 1999; 64: 1045–1055.

47. Behunova J, Klimcakova L, Zavadilikova E, et al. Methylenetetrahydrofolate reductase gene polymorphisms and neural tube defects epidemiology in the Slovak population. Birth Defects Res A Clin Mol Teratol 2010; 88: 695–700.

48. Raslova K, Bederova A, Gasparovic J, et al. Effect of diet and 677 C—> T 5,10-methylenetetrahydrofolate reductase genotypes on plasma homocyst(e)ine concentrations in Slovak adolescent population. Physiol Res 2000; 49: 651–658.

49. Stegmann K, Ziegler A, Ngo ET, et al. Linkage disequilibrium of MTHFR genotypes 677C/T-1298A/C in the German population and association studies in probands with neural tube defects (NTD). Am J Med Genet 1999; 87: 23–29.

50. Botto LD, Yang Q. 5,10-methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000; 151: 862–877.

51. Zhu H, Wicker NJ, Shaw GM, et al. Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab 2003; 78: 216–221.

52. Brody LC, Conley M, Cox C, et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: Report of the Birth Defects Research Group. Am J Hum Genet 2002; 71: 1207–1215.

53. Carroll N, Pangilinan F, Molloy AM, et al. Analysis of the MTHFD1 promoter and risk of neural tube defects. Hum Genet 2009; 125: 247–256.

54. Smithells RW, Sheppard S, Schorah CJ, et al. Possible prevention of neural tube defects by periconceptional vitamin supplementation. Lancet 1980; 1: 339–340.

55. Smithells RW, Sheppard S, Wild J, Schorah CJ. Prevention of neural tube defects recurrences in Yorkshire: final report. Lancet 1989; 2: 498–499.

56. Shaw GM, Schaffer D, Velie EM, et al. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995; 6: 219–226.

57. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993; 269: 1257–1261.

58. Berry RJ, Li Z, Erickson JD, Li S, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. collaborative project for neural tube defect prevention. N Engl J Med 1999; 341: 1485–1490.

59. Czeizel AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Genet 1996; 62: 179–183.

60. Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod Biol 1998; 78: 151–161.

61. Mašková J, Šípek A, Kollár P. A population-based control study of congenital abormalities and medication use during pregnancy using the Czech National Register of Congenital Abnormalities. Cent Eur J Med 2011; 6: 435–441.

62. Van Beynum IM, Kapusta L, Bakker MK, et al. Protective effect of periconceptional folic acid suppements on the risk of congenital heart defects: a registry-based case-control study in the northern Netherlands. Eur Heart J 2010; 31: 464–471.

63. Czeizel AE, Medveczky E. Periconceptional multivitamin supplementation and multimalformed offspring. Obstet Gynecol 2003; 102: 1255–1261.

64. Tolarova M. Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip. Lancet 1982; 2: 217.

65. Czeizel AE, Dobo M, Vargha P. Hungarian cohort controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital anomalies. Birth Defects Res 2004; 70: 853–861.

66. Wehby GL, Murray JC. Folic acid and orofacial clefts: a review of the evidence. Oral Dis 2010; 16: 11–19.

67. Czeizel AE, Tímár L, Sárközi A. Dose-dependent effect of folic acid on the prevention of orofacial clefts. Pediatrics 1999; 104: 1–7.

68. Li Z, Gindler J, Wang H, et al. Folic acid supplements during early pregnancy and likelihood of multiple births: a population-based cohort study. Lancet 2003; 361: 380–384.

69. Werler MM, Cragan JD, Wasserman CR, et al. Multivitamin supplementation and multiple births. Am J Med Genet 1997; 71: 93–96.

70. Czeizel AE, Métneki J, Dudás I. The higher rate of multiple births after periconceptional multivitamin supplementation: an analysis of causes. Acta Genet Med Gemellol (Roma) 1994; 43: 175–184.

71. Ericson A, Källén B, Aberg A. Use of multivitamins and folic acid in early pregnancy and multiple births in Sweden. Twin Res 2001; 4: 63–66.

72. Czeizel AE, Puhó EH, Langmar Z, et al. Possible association of folic acid supplementation during pregnancy with reduction of preterm birth: a population-based study. Eur J Obstet Gynecol Reprod Biol 2010; 148: 135–140.

73. Sram RJ, Binkova B, Lnenickova Z, et al. The impact of plasma folate levels of mothers and newborns on intrauterinne growth retardation and birth weight. Mut Res 2005; 591: 302–310.

74. Van der Molen EF, Verbruggen B, Nováková I, et al. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. Br J Obstet Gynaecol 2000; 107: 785–691.

75. Ferguson SE, Smith GN, Walker MC. Maternal plasma homocysteine levels in women with preterm premature rupture of membranes. Med Hypotheses 2001; 56: 85–90.

76. Dobó M, Czeizel AE. Long-term somatic and mental development of children after periconceptional multivitamin supplementation. Eur J Pediatr 1998; 157: 719–723.

77. Ortega-García JA, Ferrís-Tortajada J, Claudio L, et al. Case control study of periconceptional folic acid intake and nervous system tumors in children. Childs Nerv Syst 2010; 26: 1727–1733.

78. Ray JG, Singh G, Burrows RF. Evidence for suboptimal use of periconceptional folic acid supplements globally. BJOG 2004; 111: 399–408.

79. Kondo A, Kamihira O, Gotoh M, et al. Folic acid prevents neural tube defects: international comparison of awareness among obstetricians/gynecologists and urologists. J Obstet Gynaecol Res 2007; 33: 63–67.

80. Pötzsch S, Hoyer-Schuschke J, Seelig M, Steinbicker V. Knowledge among young people about folic acid and its importance during pregnancy: a survey in the Federal State of Saxony-Anhalt (Germany). J Appl Genet 2006; 47: 187–190.

81. Gjergja R, Stipoljev F, Hafner T, et al. Knowledge and use of folic acid in Croatian pregnant women – a need for health care education initiative. Reprod Toxicol 2006; 21: 16–20.

82. Paulik E, Császár J, Kozinszky Z, Nagymajtényi L. Preconceptional and prenatal predictors of folic acid intake in Hungarian pregnant women. Eur J Obstet Gynecol Reprod Biol 2009; 145: 49–52.

83. Rambousková J, Dlouhý P, Krízová E, et al. Health behaviors, nutritional status, and anthropometric parameters of Roma and non-Roma mothers and their infants in the Czech Republic. J Nutr Educ Behav 2009; 41: 58–64.

84. Behunová J, Podracká Ľ. Prevencia rázštepov nervovej trubice alebo, ako možno znížiť výskyt vrodených anomálii CNS? Detský Lekár 2006; 2: 19–22.

85. Czeizel AE. Folic acid: a public- -health challenge. Lancet 2006; 367: 2056.

86. US National Academy of Sciences. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline – a report of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients, Food and Nutrition Board, Institute of Medicine. Washington: National Academy Press, 1998: 1–567.

87. Simpson JL, Bailey LB, Pietrzik K, et al. Micronutrients and women of reproductive potential: required dietary intake and consequences of dietary deficiency or excess. Part I – folate, vitamin B12, vitamin B6. J Matern Fetal Neonatal Med 2010; 23: 1323–1343.

88. Almeida LC, Cardoso MA. Recommendations for folate intake in women: implications for public health strategies. Cad Saúde Pública Rio de Janeiro 2010; 26: 2011–2026.

89. Berry RJ, Bailey L, Mulinare J, et al. Fortification of flour with folic acid. Food Nutr Bull 2010; 31: S22–S35.

90. Persad VL, Van den Hof MC, Dubé JM, Zimmer P. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ 2002; 167: 241–245.

91. Liu S, West R, Randell E, et al. A comprehensive evaluation of food fortification with folic acid for the primary prevention of neural tube defects. BMC Pregnancy Childbirth 2004; 4: 20.

92. Alasfoor D, Elsayed MK, Mohammed AJ. Spina bifida an birth outcome before and after fortification of flour with iron and folic acid in Oman. East Mediterr Health J 2010; 16: 533–538.

93. Schneiderka P. Homocysteinémia a folatémia v éře fortifikace folátem. Klin Biochem Metab 2008; 16: 228–231.

94. Figueiredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009; 101: 432–435.

95. Fife J, Raniga S, Hider PN, et al. Folic acid supplementation and colorectal cancer risk: a meta-analysis. Colorectal Dis 2011; 13: 132–137.

96. Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res 2007; 51: 267–292.

97. Werler MM, Ahrens KA, Bosco JLF, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol 2011; 21: 842–850.

98. Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; 8: 75–78.

99. Sander JWAS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992; 13: 89–92.

100. Kishi T, Fujita N, Eguchi T, et al. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997; 145: 109–112.

101. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: management issues for women with epilepsy (summary statement). Neurology 1998; 51: 944–948.

102. Zahn CA, Morell ML, Collins SD, et al. Management issues for women with epilepsy: a review of the literature. Neurology 1998; 51: 949–956.

103. Wilson RD, Johnson JA, Wyatt P, et al. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. Obstet Gynaecol Can 2007; 29: 1003–1026.

104. Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. J Obstet Gynaecol Can 2006; 28: 680–689.

105. Harden CL, Meador KJ, Pennell, PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73: 133–141.

106. Kriška M, Ambrózy E, Bada V, et al. Memorix klinickej farmakológie a liekov. Bratislava: Slovak Academy Press, 2006: 1–610.

107. Súhrn charakteristických vlastností lieku Acidum folicum Léčiva. Online: http://www.adcc.sk/web/humanne-lieky/spc/acidum-folicum-leciva-spc-30013.html.

108. Vergel RG, Sanchez LR, Heredero BL, et al. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat Diagn 1990; 10: 149–152.

109. Chen G, Song X, Ji Y, et al. Prevention of NTDs with periconceptional multivitamin supplementation containing folic acid in China. Birth Defects Res A Clin Mol Teratol 2008; 82: 592–596.

110. Chan AC, van Essen P, Scott H, et al. Folate awareness and the prevalence of neural tube defects in South Australia, 1966–2007. Med J Aust 2008; 189: 566–569.

111. Thompson SJ, Torres ME, Stevenson RE, et al. Periconceptional multivitamin folic acid use, dietary folate, total folate and risk of neural tube defects in South Carolina. Ann Epidemiol 2003; 13: 412–418.